GET THE APP
Journal of Infectious Diseases & Preventive Medicine

Journal of Infectious Diseases & Preventive Medicine
Open Access

ISSN: 2329-8731

+44 1300 500008

Research Article - (2024)Volume 12, Issue 4

View PDF Download PDF

Prevalence of Influenza Associated with COVID-19 in Children

Venine Prado Saêta1, Célia Regina Malveste Ito1, Mônica de Oliveira Santos1, Lucas Candido Gonçalves Barbosa1, José Daniel Gonçalves Vieira1, Guilherme Rocha Lino de Souza2, Isabela Jubé Wastowski3, Melissa Ameloti Gomes Avelino4 and Lilian Carla Carneiro1*
 
*Correspondence: Lilian Carla Carneiro, Microorganism Biotechnology Laboratory, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Brazil, Email:

Author info »

Abstract

Acute respiratory infections can be triggered by different pathogens, including Myxovirus influenzae. All age groups can be affected by this disease, but some are more susceptible to developing complications, such as children, who can develop Severe Acute Respiratory Syndrome (SARS). Therefore, the objective of this study were to investigate the prevalence of the influenza virus and its subtypes, with COVID-19 during the pandemic period and compare it with official case data. Samples were collected from pediatric patients suspected of having a respiratory virus infection between May 2020 and April 2022 in five hospitals, totaling 606 participants, and 59 participants were selected for the study because they had an infection caused by influenza. Together, a static analysis of the Secretary of State's SARS cases was carried out and compared with the study. Data from the secretariat indicate a reduction in Covid-19, starting from week 35. For influenza, the forecast follows the seasonality of 175 epidemiological weeks, with week 32 being the one with the highest predicted quantity. The children participating in the study present numbers proportionally similar to data from the epidemiological weeks, with mortality rate of 3.38%. The data obtained present proportionally similar numbers. Influenza is one of the main etiological agents causing acute respiratory infections in children, but strategies such as vaccination, rational use of antivirals and antibiotics minimize these infections

Keywords

SARS; COVID-19; Surveillance; Epidemiology; Respiratory viruses

Introduction

Influenza is an acute respiratory infection, caused by the Myxovirus Influenzae virus belonging to the taxonomic family Orthomyxoviridae. It is a disease with high transmission and worldwide distribution. Its transmission occurs primarily through respiratory droplets produced during coughing, sneezing or talking from an otherwise susceptible infected person. Factors that promote its easy spread in epidemics, which can also cause pandemics [1,2].

Influenza infection presents different characteristics and symptoms in each individual, the most common symptoms are: Sudden onset of high fever, inflammation of the respiratory tract, headache, runny nose and cough. These manifestations occur around seven to 10 days [3].

Although the course of Influenza usually resolves spontaneously, some cases, especially in children, can progress to more serious conditions, such as Severe Acute Respiratory Syndrome (SARS). According to the protocol, SARS is described as a flu-like syndrome in any individual who presents dyspnea or one of the following signs: SpO2 saturation < or =94% in the environment, discomfort from infections or increased respiratory rate, worsening of clinical conditions underlying disease, hypotension or acute respiratory failure during the seasonal period. Furthermore, for diagnostic purposes in children, limitations of nasal alae, cyanosis, intercostal insufficiency, dehydration and in appetence must be taken into account [4].

During the COVID-19 pandemic, there was great difficulty in determining the diagnosis of Influenza. We have already seen the occurrence of continuous co-circulation between the SARS- CoV-2 virus and the Influenza virus. Infection with these two viruses generates similar symptoms, and can occur alone or simultaneously, compromising treatment [5].

Therefore, the objectives of this study were to investigate the prevalence of the Influenza virus and its subtypes, with COVID-19 in children with SARS, during the pandemic period and to compare it to official data from the Health Department of the State of Goiás, Brazil (BR).`

Materials and Methods

Ethical aspects

All sample collection and processing procedures and protocols were submitted and approved, under registration 33540320.7.0000.5078, by the Research Ethics Committee of the Hospital das Clínicas of the Federal University of Goiás, located in Goiânia-Goiás, Brazil. All parents of sick patients and volunteer donors signed the informed consent form.

Target population

This study included 606 patients with suspected respiratory virus infection, and 59 patients with Influenza infection, were selected for the study. The samples were collected in five hospitals in a capital in the Central-West region of Brazil. From May 2020 to April 2022. The following eligibility criteria were considered: Patients admitted to emergencies, Intensive Care Units (ICU), admissions to pediatric wards and hospital wards participating in the project.

Sample collection and processing

Nasal swab samples were collected for molecular analysis by RT-qPCR, in order to evaluate the presence of Parainfluenza 1, Parainfluenza 2, Parainfluenza 3, Influenza A, Influenza A (H1N1), Influenza B and SARS-COV2. All collected samples were kept at 4°C and sent to the Institute of Tropical Pathology and Public Health at the Federal University of Goiás, Goiás, Brazil. After processing, all samples were stored at -20°C. Samples were collected with a nasal swab and stored in MTV medium.

The genetic material (RNA) was extracted: Using Cellco kit® 2. Afterwards, reverse transcription was applied to obtain Complementary DNA (cDNA), using the IBMP® reverse transcriptase. The qPCR reaction was performed using the Termo Fisher® TaqMan Real-time Polymerase Chain Reaction master mix. The detection of amplification of genetic material was carried out using Applied One Step Real Time equipment.

The reverse transcription cycle followed by the PCR phase, consisted of a three to 10 seconds and denaturation step at 95°C. The DNA strands separated into single strands, followed by a hybridization step. After 15-45 seconds of polymerization at 55°C-60°C, for amplification of the primers and detection of the probes. In this step it was possible to hybridize with the single- stranded DNA templates and allow the polymerase to replicate the template, creating double-stranded DNA. This process was repeated 40 cycles. Samples were considered positive when the cycle threshold was between eight and 35.

Data from the Goiás (BR) health department and static analysis

SARS data from the Secretary of the State of Goiás (Brazil), were selected and analyzed, from the period between January 2020 and May 2023, corresponding to a total of 175 epidemiological weeks [6]. The statistical analysis of these data was carried out with the aid of Minitab® software version 19. For the analysis of seasonality and forecasting, a time series was considered with decomposition and forecast for the next 52 epidemiological weeks. Analyzes related to seasonality were considered for SARS by different etiological agents, considering COVID-19, Influenza virus and other respiratory viruses. The analysis was also carried out considering the general regardless of the etiological agent. A significance limit of 5% was considered for all statistical analyses.

Results and Discussion

Based on data from the Department of Health of the State of Goiás (BR) described in Table 1, it is possible to observe the quantities of SARS by year, age group and etiological agent (Table 1).

Year Age group SARS investigation unspecified SARS SARS by COVID-19 Influenza SARS SARS by another etiological agent SARS by another respiratory virus Total
2020 <2 years 0 541 112 5 1 144 803
2020 2 to 4 years 0 251 43 3 1 80 378
2020 5 to 9 years 3 236 52 1 4 45 341
2020 10 to 19 years 0 335 107 3 4 16 465
2020 20 to 29 years 3 677 726 7 10 13 1,436
2020 30 to 39 years 3 892 1,987 15 19 13 2,929
2020 40 to 49 years 6 1,106 3,237 7 15 16 4,387
2020 50 to 59 years 4 1,403 4,185 12 7 14 5,625
2020 >60 years 11 5,092 12,559 12 43 29 17,746
2021 <2 years 6 660 183 13 4 439 1,305
2021 2 to 4 years 6 341 98 11 0 167 623
2021 5 to 9 years 1 273 69 16 1 95 455
2021 10 to 19 years 2 314 390 12 2 18 738
2021 20 to 29 years 5 540 2,512 24 7 7 3,095
2021 30 to 39 years 10 704 7,010 6 12 10 7,752
2021 40 to 49 years 8 956 10,165 19 8 6 11,162
2021 50 to 59 years 13 1,205 11,812 20 8 9 13,067
2021 >60 years 16 4,338 21,661 124 42 33 26,214
2022 <2 years 6 923 342 58 6 707 2,042
2022 2 to 4 years 6 547 161 37 9 238 998
2022 5 to 9 years 1 416 128 46 1 128 720
2022 10 to 19 years 3 208 156 40 4 25 436
2022 20 to 29 years 5 192 318 21 4 8 548
2022 30 to 39 years 2 229 448 23 3 17 722
2022 40 to 49 years 4 307 623 26 4 11 975
2022 50 to 59 years 1 445 979 31 6 15 1,477
2022 >60 years 17 2,013 5,400 147 44 70 7,691
2023 <2 years 160 348 95 56 0 588 1,247
2023 2 to 4 years 34 198 55 33 0 94 414
2023 5 to 9 years 39 213 54 36 0 47 389
2023 10 to 19 years 19 70 21 26 0 11 147
2023 20 to 29 years 9 47 23 9 0 4 92
2023 30 to 39 years 13 49 40 19 0 2 123
2023 40 to 49 years 15 43 39 28 0 0 125
2023 50 to 59 years 24 57 67 11 0 5 164
2023 >60 years 72 272 400 46 0 19 809

Table 1: Number of SARS cases per year and age group considering the etiological agents.

During the period analyzed, the sample size was 117,640 participants, 54.6% male and 45.4% female. In 2020 and 2021, there were 23,008 and 53,900 cases of SARS due to Covid-19, respectively, and 65 and 245 cases of Influenza were reported. Until the 21st epidemiological week of 2020, 94,807 cases of hospitalization due to SARS were identified in Brazil, 31,968 cases due to COVID-19 and 1,463 due to Influenza [7].

Silva and collaborators during the analysis of the pandemic period from January to June 2020, in Pernambuco, Northeast of Brazil, determined that 66% of the SARS cases analyzed were due to COVID-19, followed by 2.5% of SARS cases due to Influenza and other respiratory diseases and 31.2% of SARS episodes had no specified cause [8].

Males were the most prevalent in reported cases, in addition, acute respiratory syndrome increased with increasing age, considering COVID-19, with 2021 standing out with 21,661 cases in the population aged >60 years. In relation to Influenza, this same age group presented 147 notifications in 2022.

In Brazil, between February 21, 2020 and September 21, 2020, 120,469 cases of hospitalization for SARS due to COVID-19 were recorded. Of these, 58.6% were men and 77.5% were aged 50 or over [9]. Data from the State of Rio Grande do Sul (BR) reported in SIVEP between January 2020 and October 3, 2020, correspond to the situation presented. 18,172 cases of SARS were confirmed, of which 54.46% were male. And the average age was 62 years old [10]. In contrast to these data, the female sex was predominant in the study developed by Binhardi, et al., for SARS cases due to Influenza A, corresponding to 54% of the samples. However, for Influenza B, males prevailed in 61.5% of reported cases [11].

Table 2 shows the main comorbidities of the epidemiological weeks analyzed. Cardiovascular diseases and diabetes were the most prevalent, demonstrating similarity with data published by other authors [12-14] (Table 2).

Year Comorbidities SARS investigation unspecified SARS SARS by COVID-19 Influenza SARS SARS by another etiological agent SARS by another respiratory virus Total
2020 Down Syndrome 0 28 48 1 0 4 81
2020 Postpartum 0 56 43 0 1 1 101
2020 Hematological disease 0 142 135 0 0 5 282
2020 Liver disease 0 159 173 0 3 4 339
2020 Pregnant 0 158 179 5 1 5 348
2020 Immunosuppression 1 487 405 1 15 11 920
2020 Asthma 1 418 518 3 2 28 970
2020 neurological disease 0 666 702 1 3 26 1398
2020 Kidney disease 0 583 853 3 4 5 1448
2020 Respiratory disease 1 726 883 1 10 14 1635
2020 Obesity 1 341 1383 1 1 5 1732
2020 Diabetes 2 1832 4982 8 11 15 6850
2020 Cardiovascular disease 3 2686 6829 11 13 22 9564
2020 Other comorbidities 6 3040 6389 13 32 54 9534
2021 Down Syndrome 1 29 110 0 0 4 144
2021 Postpartum 0 42 149 3 1 0 195
2021 Hematological disease 1 113 206 2 0 6 328
2021 Liver disease 0 125 271 5 1 1 403
2021 Pregnant 0 111 542 8 2 1 664
2021 Immunosuppression 0 286 548 7 5 22 868
2021 Asthma 1 294 798 22 1 41 1,157
2021 Neurological disease 1 542 967 11 5 34 1,560
2021 Kidney disease 2 391 1,191 5 7 4 1,600
2021 Respiratory disease 2 437 1,031 21 12 15 1,518
2021 Obesity 7 342 4,042 4 4 4 4,403
2021 Diabetes 12 1,409 8,418 30 16 11 9,896
2021 Cardiovascular disease 13 2,136 10,510 52 19 32 12,762
2021 Other comorbidities 9 2,314 13,308 45 24 101 15,801
2022 Down Syndrome 1 33 32 1 0 20 87
2022 Postpartum 0 13 27 1 0 2 43
2022 Hematological disease 0 91 94 3 2 5 195
2022 Liver disease 0 56 97 1 1 2 157
2022 Pregnant 1 45 73 7 1 3 130
2022 Immunosuppression 1 191 325 9 5 10 541
2022 Asthma 1 238 156 18 1 66 480
2022 Neurological disease 4 284 473 14 6 45 826
2022 Kidney disease 2 191 400 13 7 14 627
2022 Respiratory disease 2 316 413 31 4 23 789
2022 Obesity 0 153 305 14 2 5 479
2022 Diabetes 4 570 1,540 46 10 24 2,194
2022 Cardiovascular disease 4 880 2,060 76 20 82 3,122
2022 Other comorbidities 10 1,207 2,839 64 22 110 4,252
2023 Down Syndrome 2 10 4 2 0 11 29
2023 Postpartum 1 9 2 2 0 1 15
2023 Hematological disease 1 34 10 4 0 8 57
2023 Liver disease 0 10 9 1 0 2 22
2023 Pregnant 4 7 7 7 0 0 25
2023 Immunosuppression 6 63 33 8 0 13 123
2023 Asthma 15 92 25 12 0 25 169
2023 Neurological disease 8 66 42 17 0 17 150
2023 Kidney disease 3 44 33 4 0 2 86
2023 Respiratory disease 11 47 49 13 0 2 122
2023 Obesity 6 29 22 10 0 3 70
2023 Diabetes 33 83 123 16 0 5 260
2023 Cardiovascular disease 47 186 264 43 0 55 595
2023 Other comorbidities 35 160 148 40 0 32 415

Table 2: Number of SARS cases per year and comorbidities considering the etiological agents.

Ferdinands, et al., analyzed patients from 8 hospitals in the United States of America (USA), with Influenza and acute respiratory illness [12]. Among its results, 93% of patients had at least one comorbidity that increased the risk of complications from the flu, the most common being cardiovascular diseases, diabetes and kidney disorders. In Brazil, 196,109 deaths resulting from SARS due to COVID-19 were reported between March 22, 2020 and June 30, 2021. Of these, 42% had cardiovascular diseases, 32% diabetes mellitus, 15% high blood pressure, 8% obesity and 6% lung diseases [13].

The study by Carvalho, et al., demonstrates similar results, with cardiovascular diseases and diabetes mellitus being the most prevalent risk factors among SARS cases due to COVID-19, corresponding to 37.8% and 31.5%, respectively, of the analyzed population [14].

Bernadi, et al., developed a study with patients hospitalized with SARS, around 72.2% of participants had at least one illness prior to the period of hospitalization, the most common being systemic arterial hypertension and type 2 diabetes mellitus [15].

According to the Pan American Health Organization/WHO, the groups most susceptible to complications associated with Influenza are children under two years of age, adults over 65 years of age, pregnant/postpartum women, people with clinical morbidity such as cardiovascular disease, diabetes, kidney, lung, neurological diseases and conditions of immunosuppression and obesity [16].

In Figure 1, the time series were plotted for SARS by COVID-19, Influenza, other viruses and total SARS regardless of the etiological agent. The current scenario is represented in blue, the adjustment is represented in red, the trend is represented in green and the forecast for the next 52 epidemiological weeks (13 months) or until June 2024, (Figure 1).

physical-medicine-rehabilitation-prediction

It is possible to observe the predicted reduction for COVID-19, starting from the 35th week. The estimate becomes negative with the forecast pointing to -2.9, whereas in the last forecast week the estimate was -83.7; the forecast is for a flattening or reduction in the number of SARS due to COVID-19. For Influenza, the forecast follows the seasonality of the 175 epidemiological weeks; with week 32 being the one with the highest predicted quantity, the predicted epidemiological week correspond to January 2024. When considering the scenario of the other viruses, epidemiological week 44 stood out with the forecast with the highest number of SARS cases. When considering the general scenario, it is possible to observe the influence of SARS due to COVID-19 on the scenario.

The Influenza virus causes seasonal and endemic epidemics and periodic pandemics [17]. In countries with a temperate climate, there are clear seasonal variations, with climate and humidity favoring the survival of the virus and weakening the host's immune system. In countries with a tropical climate, there are few temperature variations and humidity conditions predominate, making the existence of seasonality patterns difficult [18].

Brazil has an extensive continental dimension, with different latitudes and six climatic subtypes (equatorial, tropical, high- altitude tropical, subtropical, temperate and semi-arid), these aspects cause Influenza epidemic peaks to occur at different times in each region [19].

Oliveira demonstrated that the South, Southeast and Center- West regions of Brazil had a higher number of cases and deaths from Influenza between the months of March and August, while in the North region the peaks occur between February and May, meaning that even July for the Northeast region [20].

The data obtained from the 59 participants aged between 0 and 13 years present numbers proportionally similar to the data from the epidemiological weeks, however, the data collected allows a more specific analysis, highlighting other respiratory viruses, such as Parainfluenza and Rhinovirus (Figure 2).

physical-medicine-rehabilitation-etiological

Of the 167,109 cases of SARS registered between 2020 and 2021 in northeastern Brazil, 63% were caused by COVID-19 and 37% were caused by other etiological agents or an unspecified cause [21].

In the study by Glória, et al., 1,366 SARS cases analyzed, 57.9% were closed as SARS due to COVID-19; the rest had no specified cause [22].

It was also possible to observe, through the data collected, the main signs and symptoms of the children analyzed, with 14 children having a cough, 13 children having a fevers, 11 children having a dyspenia and tachypnea and 9 children having a asthma. Other symptoms presented were: Nasal obstruction, diarrhea and abdominal pain, vomiting, loss of appetite. In total, two deaths were recorded (3.38%).

Second, Macías, et al., historical and more recent data show Influenza as a trigger for serious conditions, contributing to an increase in morbidity and mortality [23]. The São Paulo epidemiological bulletin published in 2022 presents children as a risk group for Influenza. Therefore, children under 2 years of age are at greater risk of hospitalization. Furthermore, children under 6 months of age have higher mortality rates [24].

The study by Sebben included 64 children aged 0 to 14 years with flu syndrome and diagnosis of Influenza A by PCR in oropharyngeal secretion [25]. The most common symptoms observed in children were fever, cough, tachypnea and intercostal and subcostal retractions. Furthermore, 20% of patients presented vomiting and/or diarrhea. Bett and colleagues would evaluate 1,169 patients aged 0 to 16 years with SARS due to Influenza [26]. The main clinical manifestations found by the authors were the association between fever, cough, dyspnea and respiratory discomfort. Therefore, fever, respiratory distress and admission to an Intensive Care Unit (ICU) demonstrated an association with death. This symptomatic picture was similar to that presented by the patients in the present study [9].

According to Harrington, et al., the Influenza virus presents known risks and constant genetic changes, posing a continuous threat to new emerging strains [27]. Given this, continuous investment must be made in the surveillance and coordination of research laboratories, risk assessment, vaccines and therapeutics. Furthermore, public health messages need to be clear and cohesive for the population.

Conclusion

Our results indicating that Influenza is among the most important agents of SARS in pediatrics. The observed epidemic period of respiratory infections can be useful for planning and implementing some prevention strategies.

Longitudinal studies should be carried out to confirm the results obtained in this medium-term study. Efficient strategies, such as the control of hospital infections caused by respiratory viruses, vaccination, rational use of antivirals and antibiotics, can be one of the many benefits generated by longitudinal studies of the clinical and epidemiological situation.

Funding

This research was funded by Capes, CNPq, FAPEG-7° PPSUS.

Competing Interests

The authors declare that they have no competing interests.

References

Author Info

Venine Prado Saêta1, Célia Regina Malveste Ito1, Mônica de Oliveira Santos1, Lucas Candido Gonçalves Barbosa1, José Daniel Gonçalves Vieira1, Guilherme Rocha Lino de Souza2, Isabela Jubé Wastowski3, Melissa Ameloti Gomes Avelino4 and Lilian Carla Carneiro1*
 
1Microorganism Biotechnology Laboratory, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Brazil
2Biochemistry and Molecular Biology Laboratory, Biologic Science Institute, Federal University of Goiás, Goiânia, Brazil
3Molecular Immunology Laboratory of Goiás State, Goiânia, Brazil
4Departament of Pediatrics, Federal University of Goiás, Goiânia, Brazil
 

Citation: Saêta VP, Ito CRM, Santos MO, Barbosa LCG, Vieira JDG, Sousa GRLD, et al. (2024) Prevalence of Influenza associated with COVID-19 in children. Infect Dis Preve Med. 12:358.

Received: 18-Mar-2024, Manuscript No. jadpr-24-30224; Editor assigned: 21-Mar-2024, Pre QC No. jadpr-24-30224 (PQ); Reviewed: 04-Apr-2024, QC No. jadpr-24-30224; Revised: 11-Apr-2024, Manuscript No. jadpr-24-30224 (R); Published: 19-Apr-2024 , DOI: 10.35841/2329-8731.24.12.358

Copyright: © 2024 Saêta VP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Sources of funding : This research was funded by Capes, CNPq, FAPEG-7° PPSUS.

Top